FAKHRAVAC

Vaccine candidate against COVID-19

FAKHRAVAC (Persian: واکسن فخرا) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III.

Nº Q107366045 ★★

Uncommon · Knowledge

FAKHRAVAC

Vaccine candidate against COVID-19

FAKHRAVAC (Persian: واکسن فخرا) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III.

Last price

—

Floor price

—

7-day median

—

30-day sales

0

30-day range

—

In circulation

0

Price history

Show table
Datemedian LowHighsales

Sales history

Last sale
—
30-day average
—
30-day low
—
30-day high
—
Sales 7d
0
Sales 30d
0

No sales yet.

Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.

From Wikipedia

FAKHRAVAC (Persian: واکسن فخرا) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III. It received emergency use authorization in Iran on 9 September 2021. The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh. According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran. Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.

Text: Wikipédia, CC BY-SA 4.0. · Image: Shared by Fars News Agency (CC BY 4.0) ·

Related cards

View card

Confirmation